| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
17,200 |
12,872 |
$772K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
14,710 |
12,134 |
$678K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
8,038 |
6,794 |
$624K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
14,176 |
11,877 |
$425K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
3,104 |
2,590 |
$360K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
856 |
732 |
$156K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,587 |
1,363 |
$109K |
| 64493 |
|
1,149 |
941 |
$68K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
432 |
374 |
$57K |
| L0650 |
Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
182 |
72 |
$52K |
| 64635 |
|
510 |
405 |
$46K |
| 27096 |
|
400 |
339 |
$37K |
| 64494 |
|
1,088 |
897 |
$33K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
467 |
322 |
$24K |
| 64495 |
|
774 |
654 |
$21K |
| 64636 |
|
327 |
169 |
$15K |
| 99215 |
Prolong outpt/office vis |
166 |
136 |
$14K |
| 64450 |
|
194 |
128 |
$10K |
| 77002 |
|
288 |
206 |
$10K |
| L0648 |
Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
14 |
14 |
$6K |
| 64640 |
|
348 |
97 |
$4K |
| 64451 |
|
54 |
30 |
$3K |
| 99205 |
Prolong outpt/office vis |
33 |
29 |
$2K |
| 62323 |
|
13 |
12 |
$1K |
| 96103 |
|
562 |
527 |
$1K |
| 64490 |
|
12 |
12 |
$734.07 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
539 |
442 |
$661.92 |
| 20553 |
|
17 |
17 |
$441.72 |
| 20552 |
|
19 |
19 |
$370.66 |
| 64492 |
|
12 |
12 |
$369.53 |
| 64491 |
|
12 |
12 |
$365.03 |
| 20610 |
|
14 |
12 |
$296.34 |
| 98967 |
|
51 |
31 |
$250.97 |
| 99422 |
|
14 |
13 |
$224.83 |
| 96127 |
|
410 |
346 |
$83.37 |
| 96146 |
|
109 |
107 |
$15.38 |